Skip to content
OmniAb
  • About
    • Overview
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antigen Design
    • Antibody Generation
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmniTaur
      • Bispecific Platforms
    • Screening
      • GEM
      • xPloration
    • Antibody Optimization
      • Fc-Silencing Technology
    • Ion Channel and Transporter Technology
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact
OmniAb
  • About
    • Overview
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antigen Design
    • Antibody Generation
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmniTaur
      • Bispecific Platforms
    • Screening
      • GEM
      • xPloration
    • Antibody Optimization
      • Fc-Silencing Technology
    • Ion Channel and Transporter Technology
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact

Bispecific Platforms: OmniFlic® and OmniClic®

  • Antibody Generation
  • OmniRat
  • OmniMouse
  • OmniChicken
  • OmniTaur
  • Bispecific Platforms

About OmniFlic: A Common Light Chain Transgenic Rat

OmniFlic was designed based on the OmniRat experience and launched in 2014. It features:

  • The same heavy chain transgenes as OmniRat
  • A single rearranged VkJk light chain for the development of bispecific, fully human antibodies
  • Antibodies that comprise a single germline Vk sequence and can be generated through comprehensive analysis of the heavy chain repertoires

Like OmniClic, OmniFlic expresses the VK3-15 light chain so antibodies generated using these platforms can be combined to form a bispecific human antibody.

About the OmniClic transgenic chicken

The OmniClic transgenic chicken was specifically developed to facilitate the generation of bispecific antibodies. It was launched in 2019.

OmniClic was engineered to:

  • Focus sequence diversity on the CDRs of the VH domain
  • Express the VH3-23 and VK3-15 light chains, with a modified light chain transgene to minimize diversification
  • Generate diverse, high-quality affinity-matured antibodies

Like OmniFlic, OmniClic expresses the VK3-15 light chain so antibodies generated using these platforms can be combined to form a bispecific human antibody.

Scientific Publications

Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for the engineering of bispecifics

Sequence-Based Discovery Demonstrates That Fixed Light Chain Human Transgenic Rats Produce a Diverse Repertoire of Antigen-Specific Antibodies

About

  • Overview
  • Team
  • Board of Directors
  • Careers

Partnerships

  • Overview
  • Why Partner with OmniAb?
  • Partner Pipeline
  • Contact Business Development

Technology

  • Overview
  • Antigen Design
  • Antibody Generation
  • Screening
  • Antibody Optimization
  • Ion Channel and Transporter Technology
  • Scientific Publications

OmniAb, Inc.
5980 Horton Street
Suite 600
Emeryville, CA 94608

[email protected]
[email protected]

Contact | Privacy Policy | Disclaimer

© 2023 OmniAb, Inc. All rights reserved.